The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Estetrol / drospirenone (Drovelis®) has been rejected for use as an oral contraceptive. The manufacture failed to make a submission for this indication.
Ferric maltol (Feraccru®) has been rejected for use in adults for the treatment of iron deficiency. The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.